$PMI

Nicotine pouches are gaining investor attention as cigarette sales decline, with brands like PMI's Zyn and BAT's Velo showing rapid growth and strong margins. BAT expects the global pouch market to grow from £4B in 2025 to £11B by 2030, with pouch volumes in Asia, Middle East, and Africa up 27.5% in H1 2026. PMI reported higher profitability for pouches compared to cigarettes and heated tobacco. Analysts note that pouch performance influences tobacco-company valuations, but wider adoption faces

Philip Morris International reported Q2 2026 net revenues of $11.2bn, up 10.4% year on year and 7.6% organically. Gross profit rose to $7.7bn and operating income to $4.5bn. Smoke-free shipments increased 7.5%, with IQOS holding a 21.5% Global Travel Retail airport offtake share (Mar-May). PMI plans $1.4bn-$1.6bn capex for 2026.

Perseverance Metals Inc. (TSXV: PMI) says its summer 2026 drill program has started at the Lac Gayot Ni-Cu-Co-PGE project in Québec, focusing on the Venus East Trend. The company plans at least 5,000 metres of drilling plus follow-up of EM anomalies and new surface zones. It also reports Voyageur drilling is delayed but rig testing should begin this week, and granted 75,000 options at $0.65.

Picard Medical, Inc. (PMI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. pmi20260720_8k.htm false 0002030617 0002030617 2026-07-17 2026-07-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event repor

Picard Medical (NYSE American: PMI), parent of SynCardia, said an independent commentary in Artificial Organs reviews its next-generation Emperor total artificial heart platform. The journal piece cites prior announcements that three acute large-animal implant procedures succeeded, with stable full circulatory support and no device-related intraoperative failures. It also notes SynCardia’s STAH is the only commercially available FDA and Health Canada-approved total artificial heart.

Picard Medical, Inc. (PMI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pmi20260626_8k.htm false 0002030617 0002030617 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event repor

Picard Medical, Inc. (PMI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pmi20260618_8k.htm false 0002030617 0002030617 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event repor

Healthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin

Healthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show

Picard Medical (NYSE American: PMI), parent of SynCardia, said it completed an acute in vivo implant study series of its next-generation Emperor Total Artificial Heart at the University of Arizona and Banner University Medical Center. Three procedures showed stable full circulatory support with no device-related intraoperative failures, using an independent dual-motor ventricular design. The Emperor TAH remains under development and is not FDA approved.